Although previous studies have demonstrated that AKT inhibitors significantly inhibit breast cancer in animal models, the dose of AKT inhibitors in animal models is high (480 mg kg−1, qw).[42] Dose restriction toxicity observed in clinical trials greatly limits the efficacy of AKT inhibitors in patients.[43] So, it is reasonable to reduce toxicity and improve efficacy by reducing the dose of AKT inhibitors through a combination treatment strategy. This evidence concerns the gene AKT1 and breast cancer.